MA27500A1 - Prevention et traitement de la maladie d'alzheimer - Google Patents

Prevention et traitement de la maladie d'alzheimer

Info

Publication number
MA27500A1
MA27500A1 MA28329A MA28329A MA27500A1 MA 27500 A1 MA27500 A1 MA 27500A1 MA 28329 A MA28329 A MA 28329A MA 28329 A MA28329 A MA 28329A MA 27500 A1 MA27500 A1 MA 27500A1
Authority
MA
Morocco
Prior art keywords
inhibitor
alzheimer
disease
prevention
treatment
Prior art date
Application number
MA28329A
Other languages
English (en)
Inventor
Thierry Canton
Laurent Pradier
Jesus Benavides
Hubert Heuer
Hans-Ludwig Schaefer
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MA27500A1 publication Critical patent/MA27500A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention a pour objet l'application des inhibiteurs de recapture intestinale de l'acide biliaire pour la prévention et le traitement de la maladie d'Alzheimer, le cas échéant en association avec un inhibiteur de HMG-CoA réductase, un inhibiteur de la capture de cholestérol, un inhibiteur de la synthèse de cholestérol ou un inhibiteur des APP secrétases.
MA28329A 2002-12-12 2005-06-10 Prevention et traitement de la maladie d'alzheimer MA27500A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0215722A FR2848452B1 (fr) 2002-12-12 2002-12-12 Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
MA27500A1 true MA27500A1 (fr) 2005-08-01

Family

ID=32338722

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28329A MA27500A1 (fr) 2002-12-12 2005-06-10 Prevention et traitement de la maladie d'alzheimer

Country Status (22)

Country Link
EP (1) EP1572174A1 (fr)
JP (1) JP2006514063A (fr)
KR (1) KR20050084250A (fr)
CN (1) CN1726016A (fr)
AR (1) AR042354A1 (fr)
AU (1) AU2003296802A1 (fr)
BR (1) BR0317280A (fr)
CA (1) CA2507945A1 (fr)
CO (1) CO5700712A2 (fr)
FR (1) FR2848452B1 (fr)
HR (1) HRP20050534A2 (fr)
MA (1) MA27500A1 (fr)
MX (1) MXPA05005556A (fr)
NO (1) NO20053341L (fr)
NZ (1) NZ540496A (fr)
PE (1) PE20040770A1 (fr)
PL (1) PL377110A1 (fr)
RS (1) RS20050420A (fr)
RU (1) RU2005121909A (fr)
TW (1) TW200503707A (fr)
WO (1) WO2004062652A1 (fr)
ZA (1) ZA200504656B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
AU2004290499C1 (en) 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
WO2005075436A2 (fr) 2004-02-05 2005-08-18 Probiodrug Ag Nouveaux inhibiteurs de la glutaminyl-cyclase
ATE523199T1 (de) 2004-11-02 2011-09-15 Univ Northwestern Pyridazinverbindungen und verfahren
CA2650711A1 (fr) 2006-04-28 2007-11-08 Northwestern University Compositions et traitements utilisant des pyridazines et des inhibiteurs de cholinesterase
MX2009012583A (es) * 2007-05-22 2010-03-08 Otsuka Pharma Co Ltd Un medicamento que comprende un derivado de carbostirilo y donepezilo para tratar enfermedad de alzheimer.
EA038594B1 (ru) 2011-10-28 2021-09-21 Шайр Хьюман Дженетик Терапис, Инк. Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
JP6217938B2 (ja) * 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2040996A1 (fr) * 1990-05-02 1991-11-03 Robert L. Albright Methode et composition permettant de reduire la cholesterolemie
EP0572560B1 (fr) * 1991-02-22 2003-01-29 SHAPIRO, Howard, K. Utilisation de composes pharmaceutiques pour le traitement de troubles associes a des affections neurologiques et a des symptomes apparentes de fa on etiologique
AU3649697A (en) * 1996-06-27 1998-01-14 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
WO1999038498A1 (fr) * 1998-01-28 1999-08-05 Warner-Lambert Company Procede pour le traitement de la maladie d'alzheimer
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19825804C2 (de) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
AU2001233299A1 (en) * 2000-02-04 2001-08-14 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents

Also Published As

Publication number Publication date
FR2848452A1 (fr) 2004-06-18
NO20053341L (no) 2005-09-07
JP2006514063A (ja) 2006-04-27
PL377110A1 (pl) 2006-01-23
HRP20050534A2 (en) 2006-11-30
TW200503707A (en) 2005-02-01
NO20053341D0 (no) 2005-07-08
ZA200504656B (en) 2006-08-30
RU2005121909A (ru) 2006-01-20
FR2848452B1 (fr) 2007-04-06
NZ540496A (en) 2008-04-30
WO2004062652A1 (fr) 2004-07-29
CO5700712A2 (es) 2006-11-30
CA2507945A1 (fr) 2004-07-29
CN1726016A (zh) 2006-01-25
AR042354A1 (es) 2005-06-15
RS20050420A (sr) 2007-04-10
BR0317280A (pt) 2005-11-08
AU2003296802A1 (en) 2004-08-10
KR20050084250A (ko) 2005-08-26
PE20040770A1 (es) 2004-12-10
EP1572174A1 (fr) 2005-09-14
MXPA05005556A (es) 2005-07-26

Similar Documents

Publication Publication Date Title
TNSN01125A1 (fr) Compositions pharmaceutiques comprenant un inhibiteur de cetp et de l'atorvastatine
GB0223040D0 (en) Therapeutic compounds
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
EP1643986A4 (fr) Inhibiteurs de la beta-secretase de phenylcarboxylate destines au traitement de la maladie d'alzheimer
PL373903A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
BR0112799A (pt) Composição farmacêutica, processo para preparação e utilização da mesma, conjunto e processo para tratamento de obesidade, utilização de um inibidor de lìpase e de um sequestrante de ácido de bìlis e processo de tratamento ou prevencão de efeitos colaterais gastrointestinais
WO2005004802A3 (fr) Inhibiteurs de la beta-secretase a base de n-alkyle phenylcarboxamide pour le traitement de la maladie d'alzheimer
EP1910829A4 (fr) Prevention et traitement d'une maladie synucleinopathique et amyloidogenique
EP1899486A4 (fr) Méthode d'identification, d'évaluation et de traitement de patients suivant un traitement anticancéreux
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
ATE368031T1 (de) Neue gamma secretase inhibitoren
EP1656359A4 (fr) Inhibiteurs macrocycliques de la beta-secretase destines au traitement de la maladie d'alzheimer
IL229124A0 (en) Inhibitors with a mutant form of kit
BR0104830A (pt) Tratamento de combinação para a demência ou déficits cognitivos associados com a doença de alzheimer e com a doença de parkinson
JO2605B1 (en) Pyrrolidone derivatives as MAOB inhibitors
NO20065117L (no) Sammensetning omfattende en JNK inhibitor og syklosporin.
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
MXPA05009986A (es) Tratamiento de la enfermedad de alzheimer.
TW200503707A (en) Application of intestinal biliary acid reuptake inhibitors for the prevention and threatment of alzheimer's disease
WO2002039122A3 (fr) Compositions et methodes permettant l'identification, l'evaluation, la prevention et la therapie des maladies cardio-vasculaires
WO2003050504A3 (fr) Methodes et compositions de traitement d'une maladie cardio-vasculaire a l'aide des genes 1419, 58765 et 2201
EP1726313A4 (fr) Medicament pour la prevention et le traitement de l'arteriosclerose
EP1669085A4 (fr) Agent therapeutique pour la prevention et/ou le traitement de la maladie d'alzheimer
WO2004028456A3 (fr) Procede et composition pour traiter des troubles neurodegeneratifs
AU2002235924A1 (en) Cyp46 genotype determination for risk and treatment evaluation of alzheimer's disease